Opko buys up cancer diagnostics player Bio-Reference in $1.47B deal

Diagnostics player Opko Health is buying Bio-Reference Laboratories for 2.75 shares of its stock for every share of Bio-Reference. The deal values Bio-Reference at $1.47 billion, according to Opko, which plans to amp up sales of the 4Kscore test, a blood test that provides a patient's specific personalized risk score for aggressive prostate cancer. Opko's stock dropped 7% on the news. The deal is expected to close in the second half of this year. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.